Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

299 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of ferric carboxymaltose on haemoglobin response among older patients with gastrointestinal bleeding: a randomised clinical trial.
Richard N, Arab-Hocine N, Vannier M, Leblanc-Boubchir R, Pelaquier A, Boruchowicz A, Musikas M, Amil M, Fumery M, Nahon S, Arotcarena R, Gelsi E, Maurin A, Hébuterne X, Savoye G. Richard N, et al. Among authors: hebuterne x. Age Ageing. 2024 May 1;53(5):afae085. doi: 10.1093/ageing/afae085. Age Ageing. 2024. PMID: 38706390 Clinical Trial.
Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study.
Beaugerie L, Brousse N, Bouvier AM, Colombel JF, Lémann M, Cosnes J, Hébuterne X, Cortot A, Bouhnik Y, Gendre JP, Simon T, Maynadié M, Hermine O, Faivre J, Carrat F; CESAME Study Group. Beaugerie L, et al. Among authors: hebuterne x. Lancet. 2009 Nov 7;374(9701):1617-25. doi: 10.1016/S0140-6736(09)61302-7. Lancet. 2009. PMID: 19837455
Portomesenteric vein thrombosis in patients with inflammatory bowel disease.
Landman C, Nahon S, Cosnes J, Bouhnik Y, Brixi-Benmansour H, Bouguen G, Colombel JF, Savoye G, Coffin B, Abitbol V, Filippi J, Laharie D, Moreau J, Veyrac M, Allez M, Marteau P; Groupe d'Etude Thérapeutique des Affections Inflammatoires du Tube Digestif. Landman C, et al. Inflamm Bowel Dis. 2013 Mar;19(3):582-9. doi: 10.1097/MIB.0b013e31827eea5f. Inflamm Bowel Dis. 2013. PMID: 23385240
Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease.
Amiot A, Grimaud JC, Peyrin-Biroulet L, Filippi J, Pariente B, Roblin X, Buisson A, Stefanescu C, Trang-Poisson C, Altwegg R, Marteau P, Vaysse T, Bourrier A, Nancey S, Laharie D, Allez M, Savoye G, Moreau J, Gagniere C, Vuitton L, Viennot S, Aubourg A, Pelletier AL, Bouguen G, Abitbol V, Bouhnik Y; Observatory on Efficacy and of Vedolizumab in Patients With Inflammatory Bowel Disease Study Group; Groupe d'Etude Therapeutique des Affections Inflammatoires du tube Digestif. Amiot A, et al. Clin Gastroenterol Hepatol. 2016 Nov;14(11):1593-1601.e2. doi: 10.1016/j.cgh.2016.02.016. Epub 2016 Feb 22. Clin Gastroenterol Hepatol. 2016. PMID: 26917043
High Risk of Anal and Rectal Cancer in Patients With Anal and/or Perianal Crohn's Disease.
Beaugerie L, Carrat F, Nahon S, Zeitoun JD, Sabaté JM, Peyrin-Biroulet L, Colombel JF, Allez M, Fléjou JF, Kirchgesner J, Svrcek M; Cancers et Surrisque Associé aux Maladies Inflammatoires Intestinales En France Study Group. Beaugerie L, et al. Clin Gastroenterol Hepatol. 2018 Jun;16(6):892-899.e2. doi: 10.1016/j.cgh.2017.11.041. Epub 2017 Dec 2. Clin Gastroenterol Hepatol. 2018. PMID: 29199142
Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort.
Tadbiri S, Peyrin-Biroulet L, Serrero M, Filippi J, Pariente B, Roblin X, Buisson A, Stefanescu C, Trang-Poisson C, Altwegg R, Marteau P, Vaysse T, Bourrier A, Nancey S, Laharie D, Allez M, Savoye G, Gilletta C, Gagniere C, Vuitton L, Viennot S, Aubourg A, Pelletier AL, Bouguen G, Abitbol V, Fumery M, Claudepierre P, Bouhnik Y, Amiot A; GETAID OBSERV-IBD study group. Tadbiri S, et al. Aliment Pharmacol Ther. 2018 Feb;47(4):485-493. doi: 10.1111/apt.14419. Epub 2017 Dec 18. Aliment Pharmacol Ther. 2018. PMID: 29250803
Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multi-centre cohort study.
Amiot A, Serrero M, Peyrin-Biroulet L, Filippi J, Pariente B, Roblin X, Buisson A, Stefanescu C, Trang-Poisson C, Altwegg R, Marteau P, Vaysse T, Bourrier A, Nancey S, Laharie D, Allez M, Savoye G, Moreau J, Vuitton L, Viennot S, Bouguen G, Abitbol V, Fumery M, Gagniere C, Bouhnik Y; OBSERV-IBD study group, the GETAID. Amiot A, et al. Aliment Pharmacol Ther. 2019 Jul;50(1):40-53. doi: 10.1111/apt.15294. Epub 2019 Jun 5. Aliment Pharmacol Ther. 2019. PMID: 31165509
299 results